Home > Industry Projects > Oncology > Erbitux (Cetuximab) - Investigational Biological
Prospects now rest on the outcome of the Merck KGaA pivotal phase III trials in colorectal and head and neck cancer.
Copyright 2007SPG Media Limited a subsidiary of SPG Media Group PLC
